Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)

Clinical trial NCT05934292 · COMPLETED

Trial details

NCT number: NCT05934292
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Hypercholesterolaemia

Start date: 2023-07-20
Primary completion: 2024-01-19
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.